Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 15/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GCG | P01275 | 5/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 1/20 | 0.45 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.44 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.44 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.44 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.44 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.44 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.44 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.44 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.44 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765722 | 0.93 | GCGR (0.52) | GCGRGCGCHRM5GLP1R | |
| SCHEMBL1765891 | 0.93 | GCGR (0.65) | GCGRGCGCHRM5GLP1RADCY6 | |
| SCHEMBL1765449 | 0.92 | GCGR (0.47) | GCGRGCGCHRM5GLP1RADCY6 | |
| SCHEMBL1765334 | 0.91 | GCGR (0.46) | GCGRGCGCHRM5GLP1RADCY6 | |
| SCHEMBL1765516 | 0.91 | GCGR (0.67) | GCGRMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1765217 | 0.91 | GCGR (0.53) | GCGRGCGADCY6ADCY3ADCY9 | |
| SCHEMBL1765763 | 0.91 | GCGR (0.62) | GCGRMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1765798 | 0.90 | GCGR (0.63) | GCGRMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1765670 | 0.90 | GCGR (0.52) | GCGRMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2274197 | 0.89 | GCGR (0.60) | GCGRGCGCHRM5GLP1RADCY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609892-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2013-12-17 | — | — | US | disclosed |
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| US-7816557-B2 | 3-{4-[1-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}-propionic acid; treat diabetic and other glucagon related metabolic disorders | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2159221-A1 | Glucagon receptor antagonists, preparation and therapeutic uses | Eli Lilly & Company (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1758853-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | GCGR 2/4885MEN1 1936/4885ALDH1A1 3337/4885 |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | GCGR 2/4885MEN1 1936/4885ALDH1A1 3337/4885 |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | GCGR 2/4885MEN1 1936/4885ALDH1A1 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.